Figure 1.
Study design and differential protein expression at peak CRS. Overview of the study design and results of the differential expression analysis. (A) Schematic depicting the course of treatment and data types collected. (B) Patient demographics and the maximum grades of CRS experienced. The median time to onset of CRS was 2 days (with interquartile range, 1-7 days). The median time to onset of the peak CRS grade was 5 days (with inter-quartile range of 2-10 days). (C) Volcano plot of proteins significantly up and down regulated at peak CRS compared to samples taken after CAR T-cell infusion from patients who never developed CRS, with dotted lines to distinguish between points with an absolute fold change >2 or <2 and a q-value < 0.05. (D) Table of proteins identified as significant in the volcano plot, with an absolute fold-change >2 or <2 and a q-value < 0.05. Axi-cel, axicabtagene ciloleucel; tisa-cel, tisagenlecleucel.

Study design and differential protein expression at peak CRS. Overview of the study design and results of the differential expression analysis. (A) Schematic depicting the course of treatment and data types collected. (B) Patient demographics and the maximum grades of CRS experienced. The median time to onset of CRS was 2 days (with interquartile range, 1-7 days). The median time to onset of the peak CRS grade was 5 days (with inter-quartile range of 2-10 days). (C) Volcano plot of proteins significantly up and down regulated at peak CRS compared to samples taken after CAR T-cell infusion from patients who never developed CRS, with dotted lines to distinguish between points with an absolute fold change >2 or <2 and a q-value < 0.05. (D) Table of proteins identified as significant in the volcano plot, with an absolute fold-change >2 or <2 and a q-value < 0.05. Axi-cel, axicabtagene ciloleucel; tisa-cel, tisagenlecleucel.

Close Modal

or Create an Account

Close Modal
Close Modal